Madan Jagasia, MD, Oncology, Nashville, TN, Vanderbilt University Medical Center

MadanJagasiaMD

Oncology Nashville, TN

Hematologic Oncology

Associate Professor, Medicine, Vanderbilt University School of Medicine

Dr. Jagasia is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Jagasia's full profile

Already have an account?

Summary

  • Dr. Madan Jagasia is an oncologist in Nashville, TN and is affiliated with multiple hospitals in the area, including Vanderbilt University Medical Center and Tennessee Valley Healthcare System. He received his medical degree from Seth G.S. Medical College and has been in practice 28 years. He also speaks multiple languages, including Hindi. He specializes in hematologic oncology and is experienced in hematologic oncology and stem cell transplantation, with a research focus on Graft-versus-host disease

Education & Training

  • Vanderbilt University
    Vanderbilt UniversityFELLOWSHIP
  • Methodist HospitalRESIDENCY
  • Nassau University Medical Center
    Nassau University Medical CenterINTERNSHIP
  • Seth G.S. Medical College
    Seth G.S. Medical CollegeMEDICAL_SCHOOL

Certifications & Licensure

  • AL State Medical License
    AL State Medical License 2020 - 2020
  • TN State Medical License
    TN State Medical License 1997 - 2021
  • AR State Medical License
    AR State Medical License 1995 - 2001
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Prospective Outcomes of Second Line Therapy in Acute Gvhd: Six Month Freedom from Treatment Failure and Day 28 Response in a Multicentre Study 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Ruxolitinib Improves Outcomes in Patients with Steroid-Refractory Graft-Versus-Host Disease
    Ruxolitinib Improves Outcomes in Patients with Steroid-Refractory Graft-Versus-Host DiseaseJune 02, 2020 09:34
  • MaaT Pharma Announces Formation of Its GvHD-Focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-Oncological Indications
    MaaT Pharma Announces Formation of Its GvHD-Focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-Oncological IndicationsMay 13, 2020 09:38
  • Longer Looks: Public Housing, Small Pox Experts, Climate Change in the Time of Coronavirus, and More
    Longer Looks: Public Housing, Small Pox Experts, Climate Change in the Time of Coronavirus, and MoreMarch 28, 2020 09:38
  • Join now to see all

Professional Memberships

Other Languages

  • Hindi

Hospital Affiliations